182 related articles for article (PubMed ID: 38236288)
1. A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients.
Wu YX; Tian BY; Ou XY; Wu M; Huang Q; Han RK; He X; Chen SL
Cancer Immunol Immunother; 2024 Jan; 73(1):14. PubMed ID: 38236288
[TBL] [Abstract][Full Text] [Related]
2. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
[TBL] [Abstract][Full Text] [Related]
3. Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving PD-1 Inhibitor Therapy.
Liang L; Li Y; Hong Y; Ji T; Chen H; Lin Z
Curr Oncol; 2023 Jul; 30(8):7189-7202. PubMed ID: 37623002
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
[TBL] [Abstract][Full Text] [Related]
7. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.
Sun XS; Xiao ZW; Liu SL; Sun R; Luo DH; Chen QY; Mai HQ
Eur Radiol; 2023 May; 33(5):3682-3692. PubMed ID: 36735041
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
10. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
11. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
12. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
[TBL] [Abstract][Full Text] [Related]
14. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
15. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
16. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
[TBL] [Abstract][Full Text] [Related]
17. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
18. An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features.
Chen X; Li Y; Li X; Cao X; Xiang Y; Xia W; Li J; Gao M; Sun Y; Liu K; Qiang M; Liang C; Miao J; Cai Z; Guo X; Li C; Xie G; Lv X
Oral Oncol; 2021 Jul; 118():105335. PubMed ID: 34023742
[TBL] [Abstract][Full Text] [Related]
19. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
